NCT06924359 · RECRUITING
Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease
This study is testing whether eye scans and blood tests can detect Alzheimer's disease earlier than current methods. Researchers will look at specific markers in the retina and in the bloodstream across people ranging from fully healthy to already diagnosed with AD. This is an observational diagnostic study, not a treatment trial, so no experimental drug or therapy is involved.
You may qualify if
- Male or female participants aged ≥ 50 years;
- Participants diagnosed with Alzheimer's Disease (AD), mild cognitive decline (MCI), subjective cognitive decline (SCD), or cognitively normal (CN);
- Signed informed consent form
You're excluded if
- Presence of other neurological disorders and systemic diseases that may cause cognitive impairment;
- Inability to cooperate with cognitive assessments;
- Refusal to undergo blood sampling.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-04-11